Editas licenses Cpf1

GEN News Highlights, 19 December 2016 http://www.genengnews.com/gen-news-highlights/editas-expands-crispr-capabilities-through-new-technology-licensing/81253581

Editas Medicine has been granted an exclusive license for the use of Cpf1 and other advanced Cas9 forms in relation to human therapies.  The Cpf1 intellectual property is owned by the Broad Institute and was initially discovered by Feng Zhang’s laboratory.  Cpf1 is distinct from Cas9 in terms of its protein structure and PAM requirements as well as being distinct intellectual property in relation to the current CRISPR patent battle.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply